

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known	
Application Number	09/709,170
Filing Date	November 10, 2000
First Named Inventor	Warrell, Raymond
Art Unit	1635
Examiner Name	Gibbs, Terra C.

Sheet

1

of

2

Attorney Docket No: GEN0008-01US

US PATENT DOCUMENTS

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"USPTO Final Office Action mailed 10/14/08 for U.S. Application Serial No. 10/738,867 filed 12/16/03", 23 pp.	
		"International Search Report for PCT/US03/41433", (01/11/2005), 3 pp.	
		CHESON, "Hematologic Malignancies: New Development and Future Treatments", Seminars in Oncology Vol. 29, No. 4 (supplement 13), (2002 Aug 29), 33-45	
		KOSMIDIS, et al., "Cisplatin/Etoposide Versus Carboplatin/Etoposide Chemotherapy and Irradiation in Small Cell Lung Cancer: A Randomized Phase III Study", Seminars in Oncology, Vol 2, No. 3 (supplement 6), (1994 Jun.), 23-30	
		LOPES, et al., "Molecular and Pharmacokinetic Properties Associated with the Therapeutics of Bcl-2 Antisense Oligonucleotide G3139 Combined with Free and Liposomal Doxorubicin", Clinical Cancer Research, Vol. 6, (2000 Jul.), 2891-2902	
		MIAYAKE, et al., "Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer with the Use of Antisense Bcl-2 Oligodeoxynucleotides", Journal of the National Cancer Institute, Vol. 92, No. 1, (2005 Jan. 5), 34-41	
		TOLCHER, "Preliminary Phase I Results of G3139 (bcl-2 Antisense Oligonucleotide) Therapy in Combination with Docetaxel in Hormone-Refractory Prostate Cancer", Seminars in Oncology, Vol. 28, No. 4 (supplement 15), (2001 Aug.), 67-70	
		JANSEN, B. et al., "Chemosensitisation of malignant melanoma by BCL-2 antisense therapy", Early Report: The Lancet, Volume 356, (Nov. 18, 2000), 1728-1733	
		MCLAUGHLIN, P. et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program", J. of Clinical Oncology, Vol. 16:8, (August 1998), 2825-2833	

EXAMINER**DATE CONSIDERED**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known	
Application Number	09/709,170
Filing Date	November 10, 2000
First Named Inventor	Warrell, Raymond
Art Unit	1635
Examiner Name	Gibbs, Terra C.

Sheet

2

of

2

Attorney Docket No: GEN0008-01US

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHI, KIM et al., "A Phase I Trial of an Antisense Oligonucleotide to BCL-2 (G3139, Genta) and Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer (HRPC)", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 1299</u> , 1 pp.	
		CHI, KIM et al., "A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide(Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer", <u>Clinical Cancer Research, vol. 7, (December 2001), 3920-3927</u>	
		BANERJEE, DEBABRATA <u>Genasense Genta Inc. Current Opinion In Investigational Drugs 2001 2(4), (2001), 574-580</u>	
		CHEN, HELEN et al., "A Phase I Study of BCL-2 Antisense G3139 (GENTA) and Weekly Docetaxel in Patients with Advanced Breast Cancer and Other Solid Tumors", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 692</u> , 1 pp.	
		SCHER, HOWARD et al., "A Phase I Trial of G3139 (Genta, Inc.), a BCL-2 Antisense Drug by Continuous Infusion (CI) as a Single Agent and with Weekly Taxol (T)", <u>Meeting: 2000 ASCO Annual Meeting, Abs. No.: 774, 1</u>	
		"International Preliminary Examination Report for PCT/US03/41433 (Sep. 13, 2005) 5 pp.",	
		IYER, et al., ""Clinical pharmacology of camptothecins"", <u>Cancer Chemother Pharmacol, (1998),42 (Suppl): S31-S-43</u>	

EXAMINER**DATE CONSIDERED**